Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 5Phase NA 3Phase 3 3Phase 1/2 3Phase 2/3 2Phase EARLY_PHASE1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Skin Neoplasms 3Neoplasms 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Melanoma 2Carcinoma, Hepatocellular 2Turcot syndrome 1Recurrence 1Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Neoadjuvant Therapy 1Mouth Neoplasms 1Malignant Ascites 1Liver Neoplasms 1Head and Neck Neoplasms 1Glioma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Small Cell 1Carcinoma, Endometrioid 1Carcinoma 1

Interventions

pembrolizumab 3Ipilimumab 3Educational Status 3Biopsy 3Optical Imaging 2Nivolumab 2Early Intervention, Educational 2Ascorbic Acid 2methyl 5-aminolevulinate 1lavender oil 1four-arm poly(ethylene oxide)-b-poly(2-(diethylamino)ethyl methacrylate) 1fludarabine phosphate 1fludarabine 1aldesleukin 1Zinc 1Water 1Trimethoprim, Sulfamethoxazole Drug Combination 1Tomography, Optical Coherence 1Toll-Like Receptor 1 1Tea 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Standard of Care 1Spermine Synthase 1Specimen Handling 1Semaxinib 1Second Harmonic Generation Microscopy 1Risk Factors 1Resistance Training 1Radiotherapy, Image-Guided 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase NA × Skin Neoplasms × pembrolizumab × Clear all
NCT05047094 2026-04-06

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

Alpha Tau Medical LTD.

Phase NA Recruiting
48 enrolled
DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Recurrence, Skin Neoplasms

NCT07436390 2026-03-02

MAK

Institute of Oncology Ljubljana

Phase NA Completed
132 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT07422779 2026-02-20

MAK

Institute of Oncology Ljubljana

Phase NA Recruiting
100 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡